Trial Profile

A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valsartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide; Valsartan
Indications Essential hypertension; Hypertension
Focus Therapeutic Use
Acronyms EVALUATE
Sponsors Novartis

13 Jun 2009 Results were presented at the 19th European Meeting on Hypertension.
03 Jun 2009 Results published in Blood Pressure Monitoring 14: 112-120, No. 3, June 2009.
19 Jun 2008 Primary efficacy results presented at ESH-ISH in June 2008

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com